Korro Bio (KRRO) EBIAT (2019 - 2025)
Korro Bio (KRRO) has disclosed EBIAT for 6 consecutive years, with -$18.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT rose 13.99% year-over-year to -$18.1 million, compared with a TTM value of -$88.4 million through Sep 2025, up 12.98%, and an annual FY2024 reading of -$83.6 million, down 2.97% over the prior year.
- EBIAT was -$18.1 million for Q3 2025 at Korro Bio, up from -$25.8 million in the prior quarter.
- Across five years, EBIAT topped out at $6.2 million in Q4 2022 and bottomed at -$39.2 million in Q4 2023.
- Average EBIAT over 5 years is -$20.4 million, with a median of -$21.0 million recorded in 2024.
- The sharpest move saw EBIAT soared 128.77% in 2022, then tumbled 734.0% in 2023.
- Year by year, EBIAT stood at -$21.5 million in 2021, then skyrocketed by 128.77% to $6.2 million in 2022, then tumbled by 734.0% to -$39.2 million in 2023, then skyrocketed by 45.95% to -$21.2 million in 2024, then grew by 14.8% to -$18.1 million in 2025.
- Business Quant data shows EBIAT for KRRO at -$18.1 million in Q3 2025, -$25.8 million in Q2 2025, and -$23.4 million in Q1 2025.